Healthcare
Sinopharm Group Co. Ltd.(SHTDF)
Live Price
Offline$2.29
+0.00% today
1Y Change
+5.05%
Window
Jun 20, 2025 → Jun 18, 2026
- Market Cap
- $50.25B
- Revenue Growth
- -4.1%
- EPS Growth
- -0.9%
- Dividend Yield
- 4.0%
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sinopharm Group Co. Ltd. (SHTDF) is a Healthcare stock with a market cap of $50.25B and listed on OTC. The stock last traded around $2.29 and up 5.0% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -4.1%, EPS growth of -0.9%, a dividend yield of 4.0%. What stands out right now is revenue -4.1%, EPS -0.9%, free cash flow +30.7% with operating margin 2.8% and ROIC 4.8%. The dividend matters to the case here, with a current yield around 4.0%. Valuation is more restrained than many high-expectation growth names at P/E 7.1 and price/sales 0.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines SHTDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-4.1% vs +7.6% peer median
Operating Margin
Below sector median
+2.8% vs +19.4% peer median
P/E
Below sector median
7.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -4.1% and EPS is at -0.9%, with operating margin around 2.8%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.0%, which matters if the thesis depends on income as much as growth.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHTDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHTDF Max Drawdown
-15.19%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SHTDF and SPY.
Company Overview
Sinopharm Group Co. Ltd.
Other OTC
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
- Leadership
- Wanyong Lian
- IPO Date
- Apr 21, 2011
- Employees
- 108.2k
- Street Address
- Sinopharm Group Building
- Mailing
- Shanghai, 200023
- Region
- Shanghai, CN
- Reporting Currency
- USD
- Investor Line
- 86 21 2305 2666
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 7.1
- EV/EBITDA
- 4.6
- Price/Sales
- 0.1
- Price/Book
- 0.6
Growth
- Revenue
- -4.1%
- EPS
- -0.9%
- Free Cash Flow
- +30.7%
Profitability
- Gross Margin
- 7.3%
- Operating Margin
- 2.8%
- Net Margin
- 1.2%
- ROE
- 8.6%
- ROIC
- 4.8%
Balance Sheet
- Debt/Equity
- 1.29
- Current Ratio
- 1.41
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.